Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 13 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 7 April 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	9,967,992		2,586,404,548
7 April 2026	260,000	235.50	61,229,022
8 April 2026	260,000	242.28	62,993,029
9 April 2026	260,000	236.25	61,424,153
10 April 2026	260,000	242.79	63,126,047
Accumulated under the programme	11,007,992		2,835,176,799

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 28,397,791 B shares of DKK 0.10 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 10 April 2026, Novo Nordisk has since 4 February 2026 repurchased a total 11,007,992 B shares at an average share price of DKK 257.56 per B share equal to a transaction value of DKK 2,835,176,799.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown [phone] [e-mail]	Liz Skrbkova (US)  [phone] [e-mail]
Investors:
Michael Novod [phone] [e-mail]	Jacob Martin Wiborg Rode [phone] [e-mail]
Max Ung [phone] [e-mail]	Sina Meyer [phone] [e-mail]
Alex Bruce [phone] [e-mail]	Christoffer Sho Togo Tullin [phone] [e-mail]
Frederik Taylor Pitter [phone] [e-mail]	Mads Berner Bruun [phone] [e-mail]

Company announcement No 25 / 2026

Attachments

• 20260413_safe harbour transaction details.JUJT
• CA260413_Safe Harbour